Nutriband (NTRB) announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA abuse deterrent transdermal technology and has the development name AVERSA FENTANYL.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRB:
- Nutriband files provisional patent application for AVERSA technology
- Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
- Nutriband reports Q2 EPS ($2.12) vs. (15c) last year
- Nutriband Issues Shares Amid Investor Engagement
- Nutriband CEO Gareth Sheridan steps aside for Irish election